1. Home
  2. ADVM vs LTRX Comparison

ADVM vs LTRX Comparison

Compare ADVM & LTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • LTRX
  • Stock Information
  • Founded
  • ADVM 2006
  • LTRX 1989
  • Country
  • ADVM United States
  • LTRX United States
  • Employees
  • ADVM N/A
  • LTRX N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • LTRX Computer Communications Equipment
  • Sector
  • ADVM Health Care
  • LTRX Telecommunications
  • Exchange
  • ADVM Nasdaq
  • LTRX Nasdaq
  • Market Cap
  • ADVM 47.4M
  • LTRX 85.6M
  • IPO Year
  • ADVM 2014
  • LTRX 2000
  • Fundamental
  • Price
  • ADVM $2.54
  • LTRX $3.02
  • Analyst Decision
  • ADVM Strong Buy
  • LTRX Strong Buy
  • Analyst Count
  • ADVM 5
  • LTRX 4
  • Target Price
  • ADVM $23.80
  • LTRX $4.13
  • AVG Volume (30 Days)
  • ADVM 312.5K
  • LTRX 295.8K
  • Earning Date
  • ADVM 08-11-2025
  • LTRX 09-04-2025
  • Dividend Yield
  • ADVM N/A
  • LTRX N/A
  • EPS Growth
  • ADVM N/A
  • LTRX N/A
  • EPS
  • ADVM N/A
  • LTRX N/A
  • Revenue
  • ADVM $1,000,000.00
  • LTRX $143,159,000.00
  • Revenue This Year
  • ADVM N/A
  • LTRX N/A
  • Revenue Next Year
  • ADVM $18.82
  • LTRX $3.66
  • P/E Ratio
  • ADVM N/A
  • LTRX N/A
  • Revenue Growth
  • ADVM N/A
  • LTRX N/A
  • 52 Week Low
  • ADVM $1.78
  • LTRX $1.91
  • 52 Week High
  • ADVM $10.14
  • LTRX $4.55
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 51.83
  • LTRX 67.14
  • Support Level
  • ADVM $2.19
  • LTRX $2.94
  • Resistance Level
  • ADVM $2.75
  • LTRX $3.11
  • Average True Range (ATR)
  • ADVM 0.22
  • LTRX 0.15
  • MACD
  • ADVM 0.04
  • LTRX 0.02
  • Stochastic Oscillator
  • ADVM 64.06
  • LTRX 85.51

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About LTRX Lantronix Inc.

Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.

Share on Social Networks: